The company said, “As of March 31, 2025, Harmony had cash, cash equivalents and investments of $610.2 million, compared to $576.1 million as of December 31, 2024.”
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HRMY:
- Harmony Biosciences Holdings, Inc. (HRMY) Q1 Earnings Cheat Sheet
- Harmony Biosciences price target lowered to $48 from $55 at UBS
- Harmony Biosciences price target lowered to $32 from $33 at BofA
- Positive Outlook for Harmony Biosciences’ ZYN002: Strong Phase 2 Data and Global Rights Support Buy Rating
- Positive Outlook for Harmony Biosciences Holdings Based on Promising ZYN-002 Study Results